Recce Pharmaceuticals Ltd. (AU:RCE) has released an update.
Recce Pharmaceuticals Ltd has completed a pivotal phase of its Phase I/II clinical trial by successfully dosing 6 subjects with a high-dose, rapid infusion of its synthetic anti-infective RECCE® 327, targeting UTI/Urosepsis treatments. Preliminary results of this cohort are imminent, as an Independent Safety Committee undertakes data review, marking a significant step towards a Phase II efficacy trial. The trial aims to establish RECCE® 327 as an effective, fast-infusion frontline treatment for UTI/Urosepsis, promising to improve patient care and reduce healthcare burdens.
For further insights into AU:RCE stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
